

# A Yu Borozinets

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4724180/publications.pdf>

Version: 2024-02-01

9  
papers

22  
citations

2258059

3  
h-index

2272923

4  
g-index

10  
all docs

10  
docs citations

10  
times ranked

34  
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinical use and cost-effectiveness of domestic blood coagulation factors VIII and IX. Pediatric Hematology/Oncology and Immunopathology, 2022, 21, 72-82.	0.3	0
2	Ethical aspects of clinical trials of blood clotting factors in children with hemophilia. , 2022, , .		0
3	Gaucher disease in children: what has changed in the 21st century. Russian Journal of Pediatric Hematology and Oncology, 2020, 6, 19-24.	0.3	1
4	FEATURES OF CLINICAL STUDIES OF RECOMBINANT COAGULATION FACTORS IDÛ IN CHILDREN WITH HEMOPHILIA Ð'. Pediatriia, 2020, 99, 168-175.	0.2	0
5	ESTIMATION OF HEMORRHAGIC SYNDROME IN PATIENTS WITH HEMOPHILIA A DURING PROFILACTIC AND ON DEMAND TREATMENT WITH OCTOFACTOR. Pediatriia, 2020, 99, 88-93.	0.2	0
6	IMMUNOGENICITY STUDY OF THE RUSSIAN RECOMBINANT ACTIVATED COAGULATION FACTOR VII IN HEMOPHILIA A PATIENTS WITH INHIBITORS. Pediatriia, 2020, 99, 206-215.	0.2	0
7	PECULIARITIES OF CLINICAL STUDIES OF RECOMBINANT COAGULATION FACTORS VIII IN CHILDREN WITH HEMOPHILIA A. Pediatriia, 2019, 98, 103-110.	0.2	0
8	Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of GlurazimÁ® (imiglucerase) in comparison with the reference product in healthy volunteers. Oncogematologiya, 2019, 14, 73-83.	0.3	3
9	Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a. Blood, 2015, 126, 4703-4703.	1.4	4